Impact of regurgitation on health-related quality of life in gastro-oesophageal re flux disease before and after short-term potent acid suppression therapy

Gut

Volumn 63, Issue 5, 2014, Pages 720-726

  Kahrilas, Peter J ^a   Jonsson, Andreas ^b   Denison, Hans ^b   Wernersson, Börje ^b   Hughes, Nesta ^c   Howden, Colin W ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b ASTRAZENECA R AND D   (Sweden)

^c OXFORD PHARMAGENESIS LTD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ESOMEPRAZOLE; LINAPRAZAN;

ARTICLE; CONTROLLED STUDY; DYSPEPSIA; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMAN; NON EROSIVE REFLUX DISEASE; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; REFLUX ESOPHAGITIS; SCORING SYSTEM; SLEEP DISORDER; SOCIAL INTERACTION; TREATMENT RESPONSE;

ANTI-REFLUX THERAPY; GASTROESOPHAGEAL REFLUX DISEASE; OESOPHAGEAL REFLUX; OESOPHAGITIS; QUALITY OF LIFE;

ANTACIDS; DRUG ADMINISTRATION SCHEDULE; ESOMEPRAZOLE; ESOPHAGITIS, PEPTIC; FOLLOW-UP STUDIES; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMANS; IMIDAZOLES; PROTON PUMP INHIBITORS; PYRIDINES; QUALITY OF LIFE; QUESTIONNAIRES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84897949891     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2013-304883     Document Type: Article

References (18)

1. van Pinxteren B, Sigterman KE, Bonis P, et al. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev 2010;11:CD002095.
2. El-Serag H, Becher A, Jones R. Systematic review: persistent reflux symptoms on proton pump inhibitor therapy in primary care and community studies. Aliment Pharmacol Ther 2010;32:720-37.
3. Donnellan C, Sharma N, Preston C, et al. Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease. Cochrane Database Syst Rev 2005;(2):CD003245.
4. Kahrilas PJ, Howden CW, Hughes N. Response of regurgitation to proton pump inhibitor therapy in clinical trials of gastroesophageal reflux disease. Am J Gastroenterol 2011;106:1419-25.
5. Kahrilas PJ, Jonsson A, Denison H, et al. Regurgitation is less responsive to acid suppression than heartburn in patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol 2012;10:612-19.
6. Kahrilas PJ, Jonsson A, Denison H, et al. Concomitant symptoms itemized in the Reflux Disease Questionnaire are associated with attenuated heartburn response to acid suppression. Am J Gastroenterol 2012;107:1354-60.
7. Vakil N, Veldhuyzen van Zanten S, Kahrilas P, et al. The Montreal definition and classification of gastro-esophageal reflux disease (GERD) - a global evidence-based consensus. Am J Gastroenterol 2006;101:1900-20.
8. Dent J, Kahrilas PJ, Hatlebakk J, et al. A randomized, comparative trial of a potassium-competitive acid blocker (AZD0865) and esomeprazole for the treatment of patients with nonerosive reflux disease. Am J Gastroenterol 2008; 103:20-6.
9. Kahrilas PJ, Dent J, Lauritsen K, et al. A randomized, comparative study of three doses of AZD0865 and esomeprazole for healing of reflux esophagitis. Clin Gastroenterol Hepatol 2007;5:1385-91. (Pubitemid 350181597)
10. Shaw MJ, Talley NJ, Beebe TJ, et al. Initial validation of a diagnostic questionnaire for gastroesophageal reflux disease. Am J Gastroenterol 2001;96:52-7. (Pubitemid 32104807)
11. Dent J, Vakil N, Jones R, et al. Accuracy of the diagnosis of GORD by questionnaire, physicians and a trial of proton pump inhibitor treatment: the Diamond Study. Gut 2010;59:714-21.
12. Wiklund IK, Junghard O, Grace E, et al. Quality of life in reflux and dyspepsia patients. psychometric documentation of a new disease-specific questionnaire (QOLRAD). Eur J Surg Suppl 1998;583:41-9. (Pubitemid 29054907)
13. Talley NJ, Fullerton S, Junghard O, et al. Quality of life in patients with endoscopy-negative heartburn: reliability and sensitivity of disease-specific instruments. Am J Gastroenterol 2001;96:1998-2004. (Pubitemid 32660889)
14. Engels LGJB, Klinkenberg-Knol EC, Carlsson J, et al. Psychometric validation of the Dutch translation of the quality of life in reflux and dyspepsia (QOLRAD) questionnaire in patients with gastroesophageal reflux disease. Health Qual Life Outcomes 2010;8:85.
15. Jones R, Junghard O, Dent J, et al . Development of the GerdQ, a tool for the diagnosis and management of gastro-oesophageal reflux disease in primary care. Aliment Pharmacol Ther 2009;30:1030-8.
16. Food and Drug Administration. Patient-reported outcome measures: use in medical product development to support labeling claims. Rockville, USA: Food and Drug Administration, 8 December 2009. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf (accessed 29 Jan 2013).
17. Sifrim D, Mittal R, Fass R, et al. Review article: Acidity and volume of the refluxate in the genesis of gastro-oesophageal reflux disease symptoms. Aliment Pharmacol Ther 2007;25:1003-15. (Pubitemid 46587688)
18. Howden CW, Forrest JA, Reid JL. Effects of single and repeated doses of omeprazole on gastric acid and pepsin secretion in man. Gut 1984;25:707-10. (Pubitemid 14086198)